Literature DB >> 20942781

Human carbonyl reductases.

Petra Malátková1, Edmund Maser, Vladimír Wsól.   

Abstract

Enzymatic carbonyl reduction means the formation of a hydroxy function out of a ketone or aldehyde moiety and applies for the metabolism of physiological (endogenous) or xenobiotic (exogenous) molecules. As for endogenous substrates, carbonyl reduction is often part of a reversible oxidoreductase process and involves the activation or inactivation of important signal molecules like steroids, prostaglandins, retinoids and biogenic amines. These reactions are carried out by NAD(P)(H)-dependent dehydrogenases belonging to two protein superfamilies, the aldo-keto reductases (AKR) and the short-chain dehydrogenases/reductases (SDR). With regard to exogenous substrates, carbonyl reduction of xenobiotics is generally a "one-way" detoxification reaction, since the resulting alcohol is easier to conjugate and to eliminate. Interestingly, the participating enzymes do also belong to the AKR and SDR superfamilies. Moreover, some enzymes from the two protein superfamilies exhibit pluripotency in that they are able to catalyze the oxidoreduction of endobiotics but do also function in the reductive metabolism of carbonyl group bearing xenobiotics. A special case are carbonyl reductases per se which belong to the SDR superfamily and whose substrates or physiological roles are not quite clear. Usually, carbonyl reductases have a broad and diverse substrate spectrum for xenobiotics, however, for some of them a specific physiological function has been speculated. In the human genome, three SDR genes have been identified to code for the carbonyl reductases CBR1 (SDR21C1), CBR3 (SDR21C2) and CBR4 (SDR45C1). The present review summarizes the current knowledge on these enzymes with special emphasis on their role as a defence system against toxicants, as well as their possible physiological function and medical application. In detail, we have screened the recent literature on these three enzymes with regard to endogenous and exogenous substrates, their three-dimensional structure, tissues specific expression, polymorphisms, transcriptional regulation, occurrence in pathological states, and their possible association with cancer. Combined, this review contributes to understanding the complex nature and biological roles(s) of the human carbonyl reductases CBR1, CBR3 and CBR4.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20942781     DOI: 10.2174/138920010794233530

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  9 in total

1.  Induction of carbonyl reductase 1 (CBR1) expression in human lung tissues and lung cancer cells by the cigarette smoke constituent benzo[a]pyrene.

Authors:  James L Kalabus; Qiuying Cheng; Raqeeb G Jamil; Erin G Schuetz; Javier G Blanco
Journal:  Toxicol Lett       Date:  2012-04-15       Impact factor: 4.372

2.  CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.

Authors:  Adolfo Quiñones-Lombraña; Nasi Li; Virginia Del Solar; G Ekin Atilla-Gokcumen; Javier G Blanco
Journal:  Biopharm Drug Dispos       Date:  2018-06       Impact factor: 1.627

3.  A molecular signature associated with prolonged survival in glioblastoma patients treated with regorafenib.

Authors:  Alessandra Santangelo; Marzia Rossato; Giuseppe Lombardi; Salvatore Benfatto; Denise Lavezzari; Gian Luca De Salvo; Stefano Indraccolo; Maria Cristina Dechecchi; Paola Prandini; Roberto Gambari; Chiara Scapoli; Gianfranco Di Gennaro; Mario Caccese; Marica Eoli; Roberta Rudà; Alba Ariela Brandes; Toni Ibrahim; Simona Rizzato; Ivan Lolli; Giuseppe Lippi; Massimo Delledonne; Vittorina Zagonel; Giulio Cabrini
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

4.  Stereospecific Metabolism of R- and S-Warfarin by Human Hepatic Cytosolic Reductases.

Authors:  Dustyn A Barnette; Bryce P Johnson; Dakota L Pouncey; Robert Nshimiyimana; Linda P Desrochers; Thomas E Goodwin; Grover P Miller
Journal:  Drug Metab Dispos       Date:  2017-06-23       Impact factor: 3.922

5.  Prostaglandin and myokine involvement in the cyclooxygenase-inhibiting drug enhancement of skeletal muscle adaptations to resistance exercise in older adults.

Authors:  Todd A Trappe; Robert A Standley; Bozena Jemiolo; Chad C Carroll; Scott W Trappe
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-12-05       Impact factor: 3.619

6.  Characterisation of the metabolites of 1,8-cineole transferred into human milk: concentrations and ratio of enantiomers.

Authors:  Frauke Kirsch; Andrea Buettner
Journal:  Metabolites       Date:  2013-01-30

7.  Monoamine Oxidase Is Overactivated in Left and Right Ventricles from Ischemic Hearts: An Intriguing Therapeutic Target.

Authors:  Maria Elena Manni; Stefania Rigacci; Elisabetta Borchi; Valentina Bargelli; Caterina Miceli; Carla Giordano; Laura Raimondi; Chiara Nediani
Journal:  Oxid Med Cell Longev       Date:  2016-12-01       Impact factor: 6.543

8.  Carbonyl reductase 1 catalyzes 20β-reduction of glucocorticoids, modulating receptor activation and metabolic complications of obesity.

Authors:  Ruth A Morgan; Katharina R Beck; Mark Nixon; Natalie Z M Homer; Andrew A Crawford; Diana Melchers; René Houtman; Onno C Meijer; Andreas Stomby; Anna J Anderson; Rita Upreti; Roland H Stimson; Tommy Olsson; Tom Michoel; Ariella Cohain; Arno Ruusalepp; Eric E Schadt; Johan L M Björkegren; Ruth Andrew; Christopher J Kenyon; Patrick W F Hadoke; Alex Odermatt; John A Keen; Brian R Walker
Journal:  Sci Rep       Date:  2017-09-06       Impact factor: 4.379

Review 9.  The indispensable role of mammalian iron sulfur proteins in function and regulation of multiple diverse metabolic pathways.

Authors:  Tracey A Rouault
Journal:  Biometals       Date:  2019-03-28       Impact factor: 2.949

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.